SPDA1
MCID: SPN225
MIFTS: 70

Spondyloarthropathy 1 (SPDA1)

Categories: Bone diseases, Genetic diseases, Immune diseases, Muscle diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Spondyloarthropathy 1

MalaCards integrated aliases for Spondyloarthropathy 1:

Name: Spondyloarthropathy 1 57 73 36
Ankylosing Spondylitis 57 11 19 42 75 73 28 41 14 16 71 31
Spondyloarthropathy, Susceptibility to, 1 57 28 12 5 38
Spondylarthritis Ankylopoietica 42 73
Marie-Strumpell Spondylitis 57 73
Bechterew Syndrome 57 73
Reiter Syndrome 73 71
Spda1 57 73
Spa 42 75
Ankylosing Spondylitis, Susceptibility to 57
Spondyloarthritis Ankylopoietica 42
Ankylosing Spondylarthritis 73
Spondylitis Ankylopoietica 42
Marie-Struempell Disease 42
Marie-Strumpell Disease 11
Spondylitis, Ankylosing 43
Axial Spondylarthritis 42
Rheumatoid Spondylitis 73
Spondylitis Ankylosans 73
Spondylitis Ankylosing 53
Spondylarthropathies 71
Arthritis, Psoriatic 71
Psoriatic Arthritis 73
Bekhterev's Disease 11
Arthritis, Reactive 71
Reactive Arthritis 73
Bekhterev Syndrome 11
Bechterew Disease 42
Spondyloarthritis 42
Spas 75

Characteristics:


Inheritance:

Multifactorial 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
overall prevalence is between 0.5 and 14 per 100,000 people per year
genetic heterogeneity (see spondyloarthropathy, susceptibility to, 2 )
spondyloarthropathy includes a spectrum of related disorders, including, 1 - ankylosing spondylitis (as), 2 - a subset of psoriatic arthritis (psa), 3 - reactive arthritis (rea), 4 - arthritis associated with inflammatory bowel disease (aibd), 5 - undifferentiated spondyloarthropathy (uspa)


Classifications:



External Ids:

Disease Ontology 11 DOID:7147
OMIM® 57 106300
OMIM Phenotypic Series 57 PS106300
ICD9CM 34 720.0
NCIt 49 C84564
SNOMED-CT 68 156619005
ICD10 31 M45
UMLS 71 C0003872 C0035012 C0038013 more

Summaries for Spondyloarthropathy 1

MedlinePlus Genetics: 42 Ankylosing spondylitis is a form of painful, ongoing joint inflammation (chronic inflammatory arthritis) that primarily affects the spine.  Early symptoms of ankylosing spondylitis typically begin between the ages of 15 and 30. Most commonly, affected individuals first experience chronic back pain and stiffness. This pain worsens with rest or inactivity, and tends to be relieved with physical activity or exercise. Pain in ankylosing spondylitis results from inflammation of the joints between the pelvic bones (the ilia) and the base of the spine (the sacrum). These joints are called sacroiliac joints, and inflammation of these joints is known as sacroiliitis. The inflammation gradually spreads to the joints between the vertebrae, eventually involving the whole spine, causing a condition called spondylitis. Over time, back movement gradually becomes limited as the bones of the spine (vertebrae) fuse together. This progressive bony fusion is called ankylosis. These fused bones are prone to fracture.Ankylosing spondylitis can involve other joints as well, including the shoulders, hips, and, less often, the knees. As the disease progresses, it can affect the joints between the spine and ribs, restricting movement of the chest and making it difficult to breathe deeply. Ankylosing spondylitis affects the eyes in more than 30 percent of cases, leading to episodes of eye inflammation called acute iritis. Acute iritis typically affects one eye at a time and causes eye pain and increased sensitivity to light (photophobia). Rarely, ankylosing spondylitis can also cause serious complications involving the heart, lungs, and nervous system. Six to 10 percent of people with ankylosing spondylitis have additional inflammatory disorders such as psoriasis, which affects the skin, or uclerative colitis or Crohn disease, which both affect the digestive tract.

MalaCards based summary: Spondyloarthropathy 1, also known as ankylosing spondylitis, is related to ankylosing spondylitis 1 and spondylitis, and has symptoms including pain, stiffness in the spine and stiffness in the neck. An important gene associated with Spondyloarthropathy 1 is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Loxoprofen and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are kyphosis and inflammation of the large intestine

MedlinePlus: 41 Ankylosing spondylitis is a type of arthritis of the spine. It causes inflammation between your vertebrae, which are the bones that make up your spine, and in the joints between your spine and pelvis. In some people, it can affect other joints. AS is more common and more severe in men. It often runs in families. The cause is unknown, but it is likely that both genes and factors in the environment play a role. Early symptoms of AS include back pain and stiffness. These problems often start in late adolescence or early adulthood. Over time, AS can fuse your vertebrae together, limiting movement. Some people have symptoms that come and go. Others have severe, ongoing pain. A diagnosis of AS is based on your medical history and a physical examination. You may also have imaging or blood tests. AS has no cure, but medicines can relieve symptoms and may keep the disease from getting worse. Eating a healthy diet, not smoking, and exercising can also help. In rare cases, you may need surgery to straighten the spine. NIH: National Institute of Arthritis and Musculoskeletal and Skin Disease

OMIM®: 57 Spondyloarthropathy (SpA), one of the commonest chronic rheumatic diseases, includes a spectrum of related disorders comprising the prototype ankylosing spondylitis (AS), a subset of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy (Miceli-Richard et al., 2004). These phenotypes are difficult to differentiate because they may occur simultaneously or sequentially in the same patient. Studies have suggested that a predominant shared component, including HLA-B27, predisposes to all phenotypic subsets, and that these subsets should be considered as various phenotypic expressions of the same disease (Said-Nahal et al., 2000, Said-Nahal et al., 2001). Braun and Sieper (2007) provided a detailed review of ankylosing spondylitis, including clinical features, pathogenesis, and management. (106300) (Updated 08-Dec-2022)

UniProtKB/Swiss-Prot: 73 A chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints.

Disease Ontology: 11 A bone inflammation disease that results in inflammation in the joints of the spine and pelvis. The disease has symptom pain, has symptom stiffness in the spine, has symptom stiffness in the neck, has symptom stiffness in the hips, has symptom stiffness in the jaw and has symptom stiffness in the rib cage.

Wikipedia: 75 Ankylosing spondylitis (AS) is a type of arthritis characterized by long-term inflammation of the joints... more...

Related Diseases for Spondyloarthropathy 1

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1625)
# Related Disease Score Top Affiliating Genes
1 ankylosing spondylitis 1 33.2 IL17A HLA-B CRP
2 spondylitis 33.0 TNFSF11 TNFRSF1A TNF NOD2 IL17A HLA-B
3 uveitis 32.3 TNFRSF1A TNF NOD2 IL17A HLA-B
4 anterior uveitis 32.1 TNF IL17A HLA-B CRP CCR6
5 back pain 32.1 MMP3 IL1RN CRP
6 ankylosis 31.9 TNFSF11 TNF IL17A CRP CCR6 BGLAP
7 reactive arthritis 31.9 TNF IL17A HLA-B CRP CD79A CCR6
8 bowel dysfunction 31.9 TNF NOD2 CRP
9 spondylarthropathy 31.8 TNFRSF1A TNF CRP
10 nail disease 31.8 TNF IL17A CCR6
11 spondyloarthropathy 31.8 TNFSF11 TNF NOD2 IL17A HLA-B CRP
12 crohn's disease 31.8 TNF NOD2 IL17A CRP CCR6
13 enthesopathy 31.7 TNF IL17A HLA-B CRP CCR6
14 inflammatory bowel disease 1 31.7 TNF NOD2 IL17A CCR6
15 psoriatic arthritis 31.6 TNFSF11 TNFRSF1B TNFRSF1A TNF NOD2 MMP3
16 osteoarthritis 31.6 TNFSF11 TNF MMP3 IL1RN IL17A CRP
17 arthropathy 31.6 TNFSF11 TNF NOD2 MMP3 IL1RN CRP
18 iritis 31.5 TNF NOD2 IL17A HLA-B CRP CCR6
19 psoriasis 31.5 TNFRSF1B TNFRSF1A TNF NOD2 IL17A HLA-B
20 synovitis 31.5 TNFSF11 TNFRSF1A TNF MMP3 IL1RN CRP
21 brucellosis 31.5 TNF IL1RN IL17A HLA-B CRP
22 juvenile rheumatoid arthritis 31.5 TNFRSF1B TNFRSF1A TNF IL1RN CRP CCR6
23 autoimmune disease 31.4 TNFRSF1B TNFRSF1A TNF IL1RN IL17A HLA-B
24 bone inflammation disease 31.4 TNFSF11 TNF MMP3 IL17A CRP CCR6
25 systemic scleroderma 31.4 TNF IL17A CRP CCR6
26 aspergillosis 31.4 TNF NOD2 IL1RN CCR6
27 ulcerative colitis 31.4 TNF NOD2 IL1RN IL17A CRP CCR6
28 arthritis 31.4 TNFSF11 TNFRSF1B TNFRSF1A TNF NOD2 MMP3
29 cartilage disease 31.4 TNF MMP3 CRP
30 periostitis 31.4 TNF IL1RN CRP
31 aortitis 31.4 TNF IL1RN IL17A CRP CCR6
32 iridocyclitis 31.3 TNF IL17A HLA-B CRP
33 glomerulonephritis 31.3 TNF IL1RN CRP CD79A CD40LG
34 interstitial lung disease 31.3 TNF IL1RN CRP CCR6
35 familial mediterranean fever 31.3 TNFRSF1A TNF NOD2 IL1RN IL17A CRP
36 rheumatoid arthritis 31.3 TNFSF11 TNFRSF1B TNFRSF1A TNF MMP3 IL1RN
37 chlamydia 31.3 TNF IL17A CRP CD79A
38 vasculitis 31.2 TNFRSF1B TNF IL17A HLA-B CRP CD79A
39 exanthem 31.2 TNF IL17A HLA-B CRP CCR6
40 urinary tract infection 31.2 TNF CRP CCR6
41 osteoporosis 31.2 TNFSF11 TNFRSF1B TNF MMP3 IL1RN IL17A
42 takayasu arteritis 31.2 TNF MMP3 HLA-B CRP
43 sarcoidosis 1 31.2 TNFRSF1B TNF NOD2 IL1RN IL17A CRP
44 urethritis 31.2 TNF IL17A CRP
45 proteasome-associated autoinflammatory syndrome 1 31.2 TNF IL1RN IL17A CRP
46 ileitis 31.1 TNF NOD2 IL17A CCR6
47 inflammatory bowel disease 31.1 TNFRSF1B TNFRSF1A TNF NOD2 MMP3 IL1RN
48 bone disease 31.1 TNFSF11 TNF CD40LG CCR6 BGLAP
49 nasopharyngitis 31.1 TNF IL17A CRP CCR6
50 demyelinating disease 31.1 TNFRSF1A TNF IL17A CCR6

Comorbidity relations with Spondyloarthropathy 1 via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential Osteoporosis
Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Spondyloarthropathy 1:



Diseases related to Spondyloarthropathy 1

Symptoms & Phenotypes for Spondyloarthropathy 1

Human phenotypes related to Spondyloarthropathy 1:

30 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 kyphosis 30 HP:0002808
2 inflammation of the large intestine 30 HP:0002037
3 back pain 30 HP:0003418
4 arrhythmia 30 HP:0011675
5 aortic regurgitation 30 HP:0001659
6 psoriasiform dermatitis 30 HP:0003765
7 enthesitis 30 HP:0100686
8 hip osteoarthritis 30 HP:0008843
9 anterior uveitis 30 HP:0012122
10 oligoarthritis 30 HP:0040313
11 sacroiliac arthritis 30 HP:0012317

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Head And Neck Eyes:
anterior uveitis

Abdomen Gastrointestinal:
inflammatory bowel disease (crohn disease and ulcerative colitis)

Skeletal Pelvis:
arthritis (hip)

Skin Nails Hair Skin:
psoriasis

Cardiovascular Heart:
aortic insufficiency
aortitis
cardiac conduction abnormalities

Skeletal Spine:
accentuated kyphosis
back stiffness
nocturnal back pain
ankylosing spondylitis
sacroiliitis
more
Skeletal Limbs:
peripheral arthritis (oligoarticular or polyarticular)
peripheral enthesitis

Laboratory Abnormalities:
hla-b27 haplotype association (95% patients)
rheumatoid factor negative

Clinical features from OMIM®:

106300 (Updated 08-Dec-2022)

Symptoms:

11
  • pain
  • stiffness in the spine
  • stiffness in the neck
  • stiffness in the hips
  • stiffness in the jaw
  • stiffness in the rib cage

UMLS symptoms related to Spondyloarthropathy 1:


back pain; sciatica; muscle cramp

GenomeRNAi Phenotypes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.02 BGLAP CD79A HLA-B IL1RN MMP3

MGI Mouse Phenotypes related to Spondyloarthropathy 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 ANKH BGLAP CCR6 CD40LG CD79A CRP
2 immune system MP:0005387 10.06 ANKH BGLAP CCR6 CD40LG CD79A CRP
3 skeleton MP:0005390 9.7 ANKH BGLAP CD40LG IL17A IL1RN MMP3
4 hematopoietic system MP:0005397 9.5 ANKH BGLAP CCR6 CD40LG CD79A HLA-B

Drugs & Therapeutics for Spondyloarthropathy 1

Drugs for Spondyloarthropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Loxoprofen Approved Phase 4 80382-23-6, 68767-14-6 3965
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
4
Pamidronic acid Approved Phase 4 40391-99-9 4674
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Sulfasalazine Approved Phase 4 599-79-1 5353980 5339 5359476
8
Certolizumab pegol Approved Phase 4 428863-50-7
9
Golimumab Approved Phase 4 476181-74-5
10
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
11
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
12
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
13
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
14
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
15
Etanercept Approved, Investigational Phase 4 185243-69-0
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
18
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
19
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
20
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
21
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
22
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
23
Ubidecarenone Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
24 Protein Kinase Inhibitors Phase 4
25 Natriuretic Peptide, Brain Phase 4
26 Cholestyramine Resin Phase 4
27 Hormones Phase 4
28 Endothelial Growth Factors Phase 4
29 Mitogens Phase 4
30 Pharmaceutical Solutions Phase 4
31 Hormone Antagonists Phase 4
32 Tripterygium Phase 4
33 Diphosphonates Phase 4
34
Triamcinolone hexacetonide Phase 4
35
Triamcinolone diacetate Phase 4
36
Triamcinolone Acetonide Phase 4 6436
37 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
38 Methylene diphosphonate Phase 4
39 Anti-Arrhythmia Agents Phase 4
40 Anesthetics Phase 4
41 Melanocyte-Stimulating Hormones Phase 4
42 Adrenocorticotropic Hormone Phase 4
43
beta-Endorphin Phase 4
44 Adrenergic alpha-Antagonists Phase 4
45 Sodium Channel Blockers Phase 4
46 Anesthetics, Local Phase 4
47 Diuretics, Potassium Sparing Phase 4
48 Tumor Necrosis Factor Inhibitors Phase 4
49 Immune Checkpoint Inhibitors Phase 4
50 Vaccines Phase 4

Interventional clinical trials:

(show top 50) (show all 943)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
3 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Unknown status NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
4 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
5 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
6 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Unknown status NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
7 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Unknown status NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
8 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
9 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
10 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
11 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB Unknown status NCT04106804 Phase 4 Abatacept 125 MG/ML
12 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Unknown status NCT04515732 Phase 4 Apremilast Oral Tablet
13 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
14 Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
15 Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh Unknown status NCT03504072 Phase 4 Tofacitinib 5 mg,;Etanercept
16 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
17 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
18 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac
19 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
20 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
21 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
22 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
23 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
24 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
25 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Completed NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
26 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 Secukinumab (AIN457) 150 mg s.c.;Placebo - Secukinumab (AIN457) 150 mg s.c.
27 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
28 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
29 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
30 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Completed NCT03733925 Phase 4 Golimumab
31 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Completed NCT02758782 Phase 4 Celecoxib
32 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
33 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
34 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
35 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
36 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
37 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
38 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
39 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
40 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Completed NCT02492217 Phase 4 Adalimumab
41 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
42 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
43 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
44 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
45 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
46 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
47 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
48 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
49 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
50 A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept

Search NIH Clinical Center for Spondyloarthropathy 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Auranofin
Aurothioglucose
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Ibuprofen
Naproxen
Naproxen sodium
Piroxicam
solufenum

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spondyloarthropathy 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells to treat ankylosing spondylitis
Embryonic/Adult Cultured Cells Related to Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells (family)
Placenta-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: spondylitis, ankylosing

Genetic Tests for Spondyloarthropathy 1

Genetic tests related to Spondyloarthropathy 1:

# Genetic test Affiliating Genes
1 Ankylosing Spondylitis 28
2 Spondyloarthropathy, Susceptibility to, 1 28

Anatomical Context for Spondyloarthropathy 1

Organs/tissues related to Spondyloarthropathy 1:

MalaCards : Bone, Eye, Skin, Bone Marrow, Placenta, Heart, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spondyloarthropathy 1:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Spondyloarthropathy 1

Articles related to Spondyloarthropathy 1:

(show top 50) (show all 30544)
# Title Authors PMID Year
1
Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. 62 57 5
8053961 1994
2
Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. 53 62 57
10861282 2000
3
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. 62 57
21743469 2011
4
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. 62 57
20062062 2010
5
Association of chromosome 2q36.1-36.3 and autosomal dominant transmission in ankylosing spondylitis: results of genetic studies across generations of Han Chinese families. 62 57
19416804 2009
6
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. 62 57
17952073 2007
7
Ankylosing spondylitis. 62 57
17448825 2007
8
Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. 62 57
15051216 2004
9
Identification of major loci controlling clinical manifestations of ankylosing spondylitis. 62 57
12905477 2003
10
Chronic synovitis and HLA B27 in patients with severe haemophilia. 62 5
12648975 2003
11
Ankylosing spondylitis, HLA B27, and beyond. 62 57
9519942 1998
12
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. 62 57
9336417 1997
13
The sex ratios of probands and of secondary cases in conditions of multifactorial inheritance where liability varies with sex. 62 57
1999831 1991
14
Relative role of genetic and environmental factors in disease expression: sib pair analysis in ankylosing spondylitis. 62 57
2912465 1989
15
Complete sequence of HLA-B27 cDNA identified through the characterization of structural markers unique to the HLA-A, -B, and -C allelic series. 62 57
3485286 1986
16
Ankylosing spondylitis is part of a multifactorial syndrome: hereditary multifocal relapsing inflammation (HEMRI). 62 57
6332689 1984
17
Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. 62 57
6606431 1983
18
Family studies in Bechterew's syndrome (ankylosing spondylitis) III. Genetics. 62 57
6604602 1983
19
HLA B27 and the genetics of ankylosing spondylitis. 62 57
107868 1978
20
Histocompatibility typing and the counseling of families with ankylosing spondylitis. 62 57
657578 1978
21
HLA B27 in ankylosing spondylitis in India. 62 57
68310 1977
22
Striking prevalence of ankylosing spondylitis in "healthy" w27 positive males and females. 62 57
126380 1975
23
HL-A27 and ankylosing spondylitis in B.C. Indians. 62 57
1185744 1975
24
Letter: Prevalence of ankylosing spondylitis. 62 57
1128613 1975
25
Ankylosing spondylitis and HL-A. A genetic disease plus? 62 57
1130424 1975
26
High association of an HL-A antigen, W27, with ankylosing spondylitis. 62 57
4688372 1973
27
Ankylosing spondylitis and HL-A 27. 62 57
4123836 1973
28
Human lymphocyte antigen association in ankylosing spondylitis. 62 57
4694299 1973
29
Genetics of ankylosing spondylitis. 62 57
6082899 1967
30
A family study of rheumatoid (ankylosing) spondylitis. 62 57
14454080 1962
31
Hereditary factors in rheumatoid arthritis and ankylosing spondylitis. 62 57
13869952 1961
32
Ankylosing spondylitis in two families showing involvement of female members only. With a search for linkage to genes determining blood group antigens. 62 57
14411096 1960
33
Heredity in ankylosing spondylitis. 62 57
13650428 1959
34
The inheritance of spondylitis rhizomelique (ankylosing spondylitis) in the K. family. 62 57
14783304 1950
35
Effect of ozone therapy on neutrophil/lymphocyte, platelet/lymphocyte ratios, and disease activity in ankylosing spondylitis: a self-controlled randomized study. 62 41
36204783 2023
36
The Impact of a Theory-Based mHealth Intervention on Disease Knowledge, Self-efficacy, and Exercise Adherence Among Ankylosing Spondylitis Patients: Randomized Controlled Trial. 62 41
36264605 2022
37
Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial. 62 41
36091030 2022
38
HLA-B27 lacking associated beta2-microglobulin rearranges to auto-display or cross-display residues 169-181: a novel molecular mechanism for spondyloarthropathies. 57
15388324 2004
39
Significant linkage to spondyloarthropathy on 9q31-34. 57
15234954 2004
40
Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. 57
11762681 2001
41
The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies. 57
10857795 2000
42
HLA-B27 and spondyloarthropathy: value for early diagnosis? 57
7562959 1995
43
HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. 57
7791441 1995
44
Familial aggregation of undifferentiated spondyloarthropathy associated with HLA-B7. 57
7702399 1995
45
A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. 57
8415702 1993
46
Autosomal dominant spondyloarthropathy: no linkage to the type II collagen gene. 57
2300126 1990
47
Autosomal dominant spondyloarthropathy. 57
2927470 1989
48
Progressive ankylosis in mice. An animal model of spondylarthropathy. I. Clinical and radiographic findings. 57
3190783 1988
49
Progressive ankylosis, a new skeletal mutation in the mouse. 57
7276519 1981
50
Joseph J. Bunim Memorial Lecture. HLA-B27 and the inheritance of susceptibility to rheumatic disease. 57
782462 1976

Variations for Spondyloarthropathy 1

ClinVar genetic disease variations for Spondyloarthropathy 1:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HLA-B HLA-B, HLA-B27 VAR Risk Factor
14908 GRCh37:
GRCh38:

Expression for Spondyloarthropathy 1

Search GEO for disease gene expression data for Spondyloarthropathy 1.

Pathways for Spondyloarthropathy 1

Pathways related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 CCR6 CD40LG CD79A CRP HLA-B IL17A
2
Show member pathways
13.54 CCR6 CD40LG IL17A IL1RN MMP3 TNF
3
Show member pathways
13.31 TNFSF11 TNFRSF1B TNFRSF1A TNF IL17A CD40LG
4
Show member pathways
13.16 CCR6 CD40LG IL17A TNF TNFRSF1A TNFRSF1B
5
Show member pathways
12.93 TNFSF11 TNFRSF1B TNFRSF1A TNF NOD2 MMP3
6
Show member pathways
12.54 TNFSF11 TNFRSF1B TNFRSF1A TNF CD40LG
7
Show member pathways
12.21 TNFSF11 TNFRSF1B TNFRSF1A TNF CD40LG
8 11.86 TNFRSF1B TNF MMP3 IL17A
9 11.75 TNF IL17A HLA-B CD40LG
10 11.74 TNFSF11 TNFRSF1B TNFRSF1A TNF IL1RN IL17A
11 11.7 TNF IL17A CCR6
12
Show member pathways
11.69 TNFRSF1B TNFRSF1A TNF
13 11.59 TNF CRP CD79A CD40LG
14 11.57 TNFSF11 TNF CD40LG
15 11.5 TNFRSF1B TNFRSF1A TNF
16
Show member pathways
11.5 TNFRSF1A TNF MMP3 CD40LG
17 11.46 TNFRSF1B TNFRSF1A TNF CD40LG
18 11.41 TNFSF11 TNF BGLAP
19 11.38 TNFRSF1A TNF NOD2 CD40LG
20
Show member pathways
11.3 TNFRSF1B TNFRSF1A TNF
21 11.29 TNFRSF1B TNFRSF1A TNF IL1RN
22 11.24 TNFRSF1B TNFRSF1A CD40LG
23 11.22 TNFRSF1B TNFRSF1A TNF
24
Show member pathways
11.22 TNFSF11 TNFRSF1B TNFRSF1A TNF CD40LG
25 11.07 TNFRSF1A TNF NOD2
26 10.71 TNFRSF1A TNF

GO Terms for Spondyloarthropathy 1

Cellular components related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.16 TNFSF11 TNFRSF1B TNFRSF1A TNF MMP3 IL1RN
2 plasma membrane GO:0005886 9.98 ANKH CCR6 CD40LG HLA-B TNF TNFRSF1A
3 plasma membrane GO:0005887 9.98 ANKH CCR6 CD40LG HLA-B TNF TNFRSF1A
4 tumor necrosis factor receptor superfamily complex GO:0002947 8.92 TNFRSF1B TNFRSF1A

Biological processes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 10.08 TNF NOD2 IL17A CRP
2 positive regulation of interleukin-12 production GO:0032735 10.03 NOD2 IL17A CD40LG
3 defense response GO:0006952 10 HLA-B NOD2 TNF TNFRSF1A
4 positive regulation of interleukin-1 beta production GO:0032731 9.92 USP50 TNF NOD2 IL17A
5 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.91 TNF NOD2 IL17A
6 positive regulation of osteoclast differentiation GO:0045672 9.88 IL17A TNF TNFSF11
7 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.87 TNF NOD2
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.86 TNFSF11 TNFRSF1B TNFRSF1A TNF
9 aortic valve development GO:0003176 9.85 TNFRSF1B TNFRSF1A
10 response to macrophage colony-stimulating factor GO:0036005 9.81 TNF BGLAP
11 negative regulation of extracellular matrix constituent secretion GO:0003332 9.8 TNFRSF1B TNFRSF1A
12 inflammatory response GO:0006954 9.8 CD40LG CRP IL17A IL1RN TNF TNFRSF1A
13 pulmonary valve development GO:0003177 9.78 TNFRSF1B TNFRSF1A
14 positive regulation of apoptotic process involved in morphogenesis GO:1902339 9.76 TNFRSF1B TNFRSF1A
15 cell communication GO:0007154 9.75 TNFSF11 TNF CD40LG
16 signaling GO:0023052 9.54 TNFSF11 TNF CD40LG
17 immune response GO:0006955 9.53 TNFSF11 TNFRSF1B TNF TAPBP IL1RN IL17A
18 regulation of osteoclast differentiation GO:0045670 9.46 TNFSF11 TNF BGLAP

Molecular functions related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor binding GO:0043120 9.46 TNFRSF1B TNFRSF1A
2 tumor necrosis factor receptor binding GO:0005164 9.43 TNFSF11 TNF CD40LG
3 cytokine activity GO:0005125 9.32 TNFSF11 TNF IL1RN IL17A CD40LG

Sources for Spondyloarthropathy 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....